Platform Updates

Mitomap and Variable Strength for ACMG now available in VarSome

By Tomas Kucera on December, 11 2019

Stay up to date

Back to main Blog
Tomas Kucera

Head of Strategic Alliances & Channel Partners


We are releasing Mitomap and Variable Strength for ACMG Criteria for the free


MitoMap [1] has been incorporated into and can now be used as a source of clinical evidence for mitochondrial DNA.

Variable Strength for ACMG Criteria

Users can manually adjust the strength of individual rules in the ACMG annotation.

VarSome's automated ACMG annotation leverages this as follows:

  • Clinical Evidence rules PP5 and BP6 may be increased from Supporting to Very Strong if reviewed by an expert committee or multiple users have submitted evidence. This is helpful in highlighting a number of well-known pathogenic variants.

ACMG PP5 Explained

  • Synonymous PS1 and alternative PM5 amino-acid rules may be downgraded to Moderate, respectively Supporting, if the clinical evidence for the alternative known-pathogenic variant is not confirmed using VarSome's ACMG classification. VarSome has also improved the behavior of these rules if the amino-acids straddle a splice site.
ACMG PM5 Explained

These changes will only be applied to, for the moment, but we expect to be releasing them for VarSome Clinical, in the near future.


The following variant related to Myopathy would be rated Uncertain Significance without the additional weighting of the clinical evidence for PP5.


This example also highlights the benefit of the many users contributing to the platform.

In conclusion

As ever, we hope that you find useful, and we are continually striving to improve the platform. Do please contact us if you notice any issues or have suggestions on how to improve the platform.

Presenting VarSome Clinical

Learn about VarSome Clinical




Submit a Comment

Stay up to date